Literature DB >> 32585139

Multiple doses of umbilical cord blood cells improve long-term brain injury in the neonatal rat.

Tayla R Penny1, Yen Pham2, Amy E Sutherland2, Jamie G Mihelakis2, Joohyung Lee3, Graham Jenkin1, Michael C Fahey4, Suzanne L Miller1, Courtney A McDonald5.   

Abstract

BACKGROUND: Hypoxic ischemic (HI) insults during pregnancy and birth can result in neurodevelopmental disorders, such as cerebral palsy. We have previously shown that a single dose of umbilical cord blood (UCB) cells is effective at reducing short-term neuroinflammation and improves short and long-term behavioural outcomes in rat pups. A single dose of UCB was not able to modulate long-term neuroinflammation or brain tissue loss. In this study we examined whether multiple doses of UCB can modulate neuroinflammation, decrease cerebral tissue damage and improve behavioural outcomes when followed up long-term.
METHODS: HI injury was induced in postnatal day 10 (PND10) rat pups using the Rice-Vannucci method of carotid artery ligation. Pups received either 1 dose (PND11), or 3 doses (PND11, 13, 20) of UCB cells. Rats were followed with behavioural testing, to assess both motor and cognitive outcomes. On PND50, brains were collected for analysis.
RESULTS: HI brain injury in rat pups caused significant behavioural deficits. These deficits were significantly improved by multiple doses of UCB. HI injury resulted in a significant decrease in brain weight and left hemisphere tissue, which was improved by multiple doses of UCB. HI resulted in increased cerebral apoptosis, loss of neurons and upregulation of activated microglia. Multiple doses of UCB modulated these neuropathologies. A single dose of UCB at PND11 did not improve behavioural or neuropathological outcomes.
CONCLUSIONS: Treatment with repeated doses of UCB is more effective than a single dose for reducing tissue damage, improving brain pathology and restoring behavioural deficits following perinatal brain injury.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Behaviour; Hypoxia ischemia; Long-term; Stem cells; Umbilical cord blood

Year:  2020        PMID: 32585139     DOI: 10.1016/j.brainres.2020.147001

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  Rationale for the Use of Cord Blood in Hypoxic-Ischaemic Encephalopathy.

Authors:  Izabela Zdolińska-Malinowska; Dariusz Boruczkowski; Dominika Hołowaty; Paweł Krajewski; Emilian Snarski
Journal:  Stem Cells Int       Date:  2022-05-11       Impact factor: 5.131

2.  Umbilical cord blood CD34+ cells administration improved neurobehavioral status and alleviated brain injury in a mouse model of cerebral palsy.

Authors:  Yanqun Chang; Shouheng Lin; Yongsheng Li; Song Liu; Tianbao Ma; Wei Wei
Journal:  Childs Nerv Syst       Date:  2021-02-09       Impact factor: 1.475

3.  Umbilical Cord Blood and Cord Tissue-Derived Cell Therapies for Neonatal Morbidities: Current Status and Future Challenges.

Authors:  Lindsay Zhou; Courtney McDonald; Tamara Yawno; Graham Jenkin; Suzanne Miller; Atul Malhotra
Journal:  Stem Cells Transl Med       Date:  2022-03-17       Impact factor: 6.940

4.  Lack of Neuroprotection with a Single Intravenous Infusion of Human Amnion Epithelial Cells after Severe Hypoxia-Ischemia in Near-Term Fetal Sheep.

Authors:  Joanne O Davidson; Lotte G van den Heuij; Simerdeep K Dhillon; Suzanne L Miller; Rebecca Lim; Graham Jenkin; Alistair J Gunn; Laura Bennet
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

5.  Umbilical cord blood therapy modulates neonatal hypoxic ischemic brain injury in both females and males.

Authors:  Tayla R Penny; Yen Pham; Amy E Sutherland; Joohyung Lee; Graham Jenkin; Michael C Fahey; Suzanne L Miller; Courtney A McDonald
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.379

6.  Effect of expansion of human umbilical cord blood CD34 + cells on neurotrophic and angiogenic factor expression and function.

Authors:  Ashalyn P Watt; Mark Kirkland; Lakshmi Nekkanti; Yen Pham; Courtney McDonald; Atul Malhotra; Guy Moeneclaey; Suzanne L Miller; Graham Jenkin
Journal:  Cell Tissue Res       Date:  2022-02-02       Impact factor: 5.249

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.